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Abstract
Background: The hepatitis C virus (HCV) infects nearly 3% of the World’s population, causing severe liver disease in
many. Standard of care therapy is currently pegylated interferon alpha and ribavirin (PegIFN/R), which is effective in
less than half of those infected with the most common viral genotype. Two IL28B single nucleotide polymorphisms
(SNPs), rs8099917 and rs12979860, predict response to (PegIFN/R) therapy in treatment of HCV infection. These
SNPs were identified in genome wide analyses using Illumina genotyping chips. In people of European ancestry,
there are 6 common (more than 1%) haplotypes for IL28B, one tagged by the rs8099917 minor allele, four tagged
by rs12979860.
Methods: We used massively parallel sequencing of the IL28B and IL28A gene regions generated by polymerase
chain reaction (PCR) from pooled DNA samples from 100 responders and 99 non-responders to therapy, to identify
common variants. Variants that had high odds ratios and were validated were then genotyped in a cohort of 905
responders and non-responders. Their predictive power was assessed, alone and in combination with HLA-C.
Results: Only SNPs in the IL28B linkage disequilibrium block predicted drug response. Eighteen SNPs were
identified with evidence for association with drug response, and with a high degree of confidence in the sequence
call. We found that two SNPs, rs4803221 (homozygote minor allele positive predictive value (PPV) of 77%) and
rs7248668 (PPV 78%), predicted failure to respond better than the current best, rs8099917 (PPV 73%) and
rs12979860 (PPV 68%) in this cross-sectional cohort. The best SNPs tagged a single common haplotype, haplotype
2. Genotypes predicted lack of response better than alleles. However, combination of IL28B haplotype 2 carrier
status with the HLA-C C2C2 genotype, which has previously been reported to improve prediction in combination
with IL28B, provides the highest PPV (80%). The haplotypes present alternative putative transcription factor binding
and methylation sites.
Conclusions: Massively parallel sequencing allowed identification and comparison of the best common SNPs for
identifying treatment failure in therapy for HCV. SNPs tagging a single haplotype have the highest PPV, especially
in combination with HLA-C. The functional basis for the association may be due to altered regulation of the gene.
These approaches have utility in improving diagnostic testing and identifying causal haplotypes or SNPs.
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Some 3% of the World’sp o p u l a t i o ni si n f e c t e dw i t ht h e
hepatitis C virus (HCV). In most cases, the virus, if either
untreated or treated but not cleared, causes chronic
infection and thereby increases the risk of liver failure
and liver cancer. HCV infection is also the major cause of
liver transplantation. It is consequently desirable to eradi-
cate the virus before end stage liver disease develops and
to improve transplant outcomes by preventing reinfec-
tion in the transplanted liver. The current standard of
care is pegylated interferon and ribavirin, which clears
the virus only after weekly injections for up to 48 weeks
and in less than half of those infected with the most com-
mon form of the virus, genotype 1.
In 2009, four independent groups, using genome wide
association studies (GWAS), identified SNPs from the
IL28B (RefSeq accession [RefSeq:NM_172139]) region
that could predict drug response [1-4]. A further study
demonstrated that viral clearance without therapy was
also predicted by these SNPs [5]. Previously, prediction
of treatment failure was based on phenotypic features
such as viral load, body mass index, ethnicity, and liver
fibrosis. IL28B genotype, however, predicts treatment
failure with greater sensitivity and specificity. Subse-
quently, serum IP10 [6], 25 hydroxy vitamin D3 [7], and
hepatic ISG expression from biopsies were also found to
predict response [8]. Combinations of these factors, the
IL28B genotype, and the HLA-C genotype [9] have pro-
ven effective in predicting therapeutic response.
It is desirable to predict treatment response for a num-
b e ro fr e a s o n s .F o rt h o s eu n l i k e l yt or e s p o n d ,a l t e r n a t i v e
therapies are in late phase clinical trials and have a
greatly improved success rate due to the ability to target
those that are unlikely to respond to the standard treat-
ment. Patients with non-response genotypes could there-
fore delay treatment, or have preferential use of the more
expensive new therapies, which are all designed to be
used in combination with the current standard of care.
The predictive value of SNPs is best calculated from rou-
tine clinical practice, rather than the clinical trial sce-
nario, since these are the conditions in which most
patients are treated and where there is usually much
lower compliance with drug usage regimens. Conse-
quently, in this study we used a cross-sectional cohort to
compare response rates for the different SNPs.
Other groups [1,2] used Sanger sequencing of the coding
region of IL28B, or genotyping of previously identified
SNPs from this region or the flanking regions [10,11] to
search for SNPs not on the GWAS chips which might pre-
dict drug response with higher specificity or sensitivity.
Here we describe our use of massively parallel sequencing
(MPS) to detect SNPs or indels over the 100 kb around
IL28B. MPS allows the high throughput detection of new
and less common variants and is now a routine follow up
for GWAS hits. MPS may identify further variants better
able to predict drug response than those discovered
through the GWAS SNP chip design, which usually only
detects association by proxy, or indirect association, i.e.
does not identify the causal variants. Thus, newly discov-
ered variants could include the identification of additional
haplotype tagging SNPs, SNPs that did not tag haplotypes,
less common SNPs with better predictive values than the
common haplotypes, and possibly synthetic SNPs that
were tagged by the response haplotypes.
MPS is still an expensive technology. Thus the most
suitable design for re-sequencing of a GWAS hit is cur-
rently via a pooling strategy. Such a strategy will only
have limited power to identify rare variants.
The IL28B region
IL28B lies next to two related genes, IL28A (NM_172138)
and IL29 (NM_172140), on chromosome 19 (Figure 1,
[12]). The three genes are thought to have evolved via two
gene duplication events [13]. The resulting degree of
homology makes sequencing and alignment in this region
particularly challenging, with the problem particularly
acute for IL28A and IL28B, which share identity for 1309
bases over a 1339 bp length. Anticipating this problem, we
chose to perform paired-end sequencing, which allows a
read pair to be unambiguously mapped if one end can be
unambiguously mapped, regardless of whether the other
end maps to multiple locations. However, due to the
extended region of similarity, it remains possible that both
reads of a pair may map to multiple locations.
Methods
Ethics statement and study subjects
Ethical approval was obtained from the Human Research
Ethics Committees of Sydney West Area Health Service
and the University of Sydney. All other sites had ethical
approval from their respective ethics committees. Writ-
ten informed consent was obtained from all participants.
Characteristics of each cohort are shown in Table 1. All
treated patients were infected with genotype 1, received
pegylated interferon and ribavirin (PegIFN/R), and had
virological response determined 6 months after comple-
tion of therapy. The diagnosis of chronic hepatitis C was
based on appropriate serology and presence of HCV
RNA in serum. All sustained virological responders
(SVRs) and non-SVR cases received therapy for 48 weeks
except when HCV RNA was present with a < 2 log drop
in RNA level after 12 weeks therapy. Patients were classi-
fied as having had a sustained virological response (SVR)
if they were HCV PCR negative, 6 months after the end
of therapy. Patients were excluded if they had been co-
infected with either hepatitis B virus (HBV) or human
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Figure 1 UCSC screenshot of the chromosome 19 region containing IL28A, IL28B and IL29. Coordinates are from hg19. IL28A and IL28B lie
within segmental duplications. The locations of these duplications are reflected in areas of poor mapability, as indicated by low scores on the
CRG Align 75 subtrack. The score for this subtrack is the reciprocal of the number of matches found in the genome for 75 mers with no more
than 2 mismatches. The track below this subtrack shows the location of the 19 SNPs that were individually genotyped using Sequenom. The
four SNPs that best tagged the IL28B region haplotypes are indicated in blue. Screenshot taken from UCSC draft human genome [28].
Table 1 Demographic characteristics of chronic hepatitis C patients after therapy
Demographic factors
a
Gender
Mean years of age (SD) Females Males Mean BMI (SD) Viral load
c
Australian cohort (n = 312,313)
SVR (n = 130) 40.0
a (9.6) 52
b (40.0) 78
b (60.0) 26.927.0 (4.85.1) P =N S
NSVR (n = 182,183) 44.5 4
a (7.12) 42 43
b (23.15) 140
b (76.95) 27.4 (5.32)
Berlin cohort (n = 310,307)
SVR (n = 150,149) 41.0 (10.5) 79 78 (52.73) 71 (47.37) 25.1 (4.5) P < 0.05001
NSVR (n = 15,860) 46.7 8 (10.34) 69 68 (43.10) 91 90 (55.97.0) 25.9 (3.9)
Newcastle UK cohort (n = 6,990)
SVR (n = 3,140) 3837.2
a (11.86) 9 12 (29.030.0) 22 28 (7170.0) 25.23.7 (3.96.3) P ≤ 0.05002
NSVR (n = 5,038) 46.0
a (1210.0) 10 12 (26.324.0) 28 38 (73.776.0) 26.227.0 (6.64.8)
Bonn cohort (n = 57)
SVR (n = 26) 44.7 (12.9) 11 (42.3) 15 (57.7) 25.4 (4.23) P ≤ 0.05008
NSVR (n = 31) 50.8 (10.9) 11 (35.5) 20 (64.5) 27.3 (4.6)
Trent UK cohort (n = 4,843)
SVR (n = 2,221) 39.843.5 (9.80) 6 5 (27.323.8) 16 (72.776.2) 26.97.1 (3.57) NS
NSVR (n = 2,622) 45.747.4 (7.99.3) 5 4 (1918.2) 21 18 (8081.8) 2526.0 (2.93.5)
Turin cohort (n = 11,495)
SVR (n = 5,845) 41.63.3 (13.10) 28 18 (48.340.0) 30 27 (51.760.0) 24.023.9 (3.23) P ≤ 0.0502
NSVR (n = 5,650) 45.1 7 (10.09.7) 19 (33.938.0) 37 31 (66.162.0) 24.5 6 (3.34)
Total cohort (n = 910,905)
SVR (n = 417,411) 40.9 6
a (10.87) 185 176
b (44.442.8) 232 235
b (55.657.2) 25.5 7 (4.75) P < 0.05001
NSVR (n = 493,494) 45.7
b 8
a (9.32) 156
b 157
b (31.68) 337
b (68.42) 26.3 5 (4.76)
aP < 0.001 comparisons between responders (SVR) and non-responders (NSVR) based on Student’s t-testUnless otherwise specified, mean (s.d.) are presented.
bP < 0.05 005 comparisons between responders (SVR) and non-responders (NSVR) based on the c
2 test.
cComparisons between SVR and NSVR based on the
Mann-Whitney U test.
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opean descent.
Massively parallel sequencing of DNA pools
The study design is illustrated in Figure 2. DNA samples
from 100 of the 131 responders studied by Suppiah et al
were pooled to create a responder DNA pool, while
DNA samples from 99 of the 162 non-responders were
pooled to create a non-responder DNA pool. DNA sam-
ples were not barcoded.
Long-range PCR was used to amplify a continuous 100
kbp region of DNA containing the IL28A, IL28B,a n d
IL29 genes. Specifically, 23 overlapping amplicons of size
4800-5273 bp were used to amplify chr19:39,709,944-
39,809,945 (human genome version hg19). The PCR pro-
ducts from each pool were sequenced using a lane on an
Illumina Genome Analyzer II flowcell, with 75 bp paired-
end reads generated. Raw read quality was examined
using FASTQC version 0.7.0 [14]. Genotype data has
been deposited at the European Genome-phenome
Archive (EGA) [15], which is hosted by the EBI, under
accession number [EBI:EGAS00001000096].
Alignment and post-processing
Reads from each pool were aligned separately to hg19
using version 0.5.8a of BWA [16]. Up to four mismatches
were permitted across the length of each read, including
up to four mismatches in the 32 bp seed. Bases with
Phred quality scores of less than three were trimmed
from the ends of reads.
Reads corresponding to the target region were extracted
using SAMtools [17]. Reads with a mapping quality of zero
were discarded. This discards reads mapped as singletons
w h i c hd on o ta l i g nt ou n i q u el o c a t i o ni nt h eg e n o m e ,a s
well as read pairs where neither end maps to a unique
location.
Considering the small size of the target region, the
large number of haplotypes present, and the depth of
sequencing, we expected a substantial proportion of read
pairs aligning to the same location to be biological rather
than PCR duplicates. Hence, duplicate removal was not
performed.
Variant calling and association testing using pooled DNA
Variant calling was performed using version 3 of CRISP
[18], a variant detection algorithm designed specifically
for pooled DNA samples. Default settings were used
(minimum read mapping/base quality to consider a read/
base for variant calling 10; ≥ 1r e a ds u p p o r t i n gv a r i a n t
must have mapping quality ≥ 20; ≥ 4 reads per pool; con-
tingency table threshold p = 10
-3; quality values based
p-value threshold 10
-5).
Fisher’s exact test was used to compare the proportion
of each allele in responders and non-responders at var-
iant sites. If the total number of allele counts for a cohort
exceeded the number of chromosomes, allele counts
were rescaled so that they summed to the number of
chromosomes in the cohort.
Validation with original GWAS SNP data
15 SNPs within the 100 kbp target region were individu-
ally genotyped as part of the original GWAS. For these
SNPs, we are able to compare the minor allele frequencies
(MAFs), odds ratios and Fisher exact p-values estimated
from pooled MPS data to those obtained from individual
genotyping results. Correlation between the two sets of
Figure 2 SNP selection scheme.
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coefficient.
We also compared MAFs from pooled MPS to MAFs
from CEPH genotypes, obtained from Utah residents
with ancestry from northern and western Europe (CEU),
for the 35 SNPs in the target region which were studied
as part of the HapMap project [19].
Validation using individual genotyping
19 putative single nucleotide variants (SNVs) were chosen
for validation using individual genotyping based on the
MPS results and/or biological grounds. We ranked the
MPS SNPs by Fisher’s exact test and rejected SNPs with p-
values exceeding 10
-3. Only SNPs supported by reads align-
ing in both directions and covered by at least 1000 reads in
at least one pool were chosen. Of these 47 SNPs remaining
we then excluded those failing Sequenom genotyping algo-
rithms (excludes SNPs which are in highly homologous
regions, have multiple genomic targets, or are close to
other variants which may confound the genotyping). This
left us with 19 SNPs, all included in dbSNP132. Ten had
been genotyped in previous studies, and we genotyped the
remainder in a single multiplex Sequenom reaction. The
validation cohort comprised 905 samples from six different
cohorts from Australia, the UK, Germany and Italy. 312
individuals were from our original GWAS (this includes
the 199 patients who were in the R and NR pools), 581
from the replication phase, and 43 samples were not in the
GWAS. Three SNPs (rs8105790, rs8103142 and rs628973)
were not genotyped for 324 samples and 43 samples were
not genotyped for five SNPs (rs10853727, rs8109886,
rs10853728, rs12980602, rs4803224).
Genotype cleaning was performed using PLINK [20].
Accounting for obligate missingness, we discarded samples
with a genotyping rate of below 89.47% (corresponding to
less than 17/19 SNPs being assigned a genotype), and
SNPs with (i) a genotyping rate below 90%, (ii) a minor
allele frequency (MAF) below 1%, or (iii) a combined sam-
ple Hardy Weinberg test p-value below 10
-10.W eu s e d
Pearson’s chi-square test to test for differential missing-
ness of SNPs between responders and nonresponders.
Single marker association analyses were also performed
using PLINK. We combined genotypes from the six
cohorts and performed tests of association under allelic,
genotypic, recessive and dominant genetic models. We
also performed a fixed-effects meta-analysis for the allelic
test; this was not deemed advisable under other genetic
models as low or zero genotype counts resulted for some
SNP/cohort combinations.
Linkage disequilibrium (LD) was estimated and haplo-
type frequencies inferred using Haploview [21]. The fre-
quencies of common haplotypes (> = 1%) were compared
between non-responders and responders using odds
ratios, with 95% confidence intervals calculated using
Woolf’s formula and p-values calculated using Pearson’s
chi-square test.
Results
Massively parallel sequencing
The test and validation cohorts have been described
previously, and their demographic features are sum-
marised in Table 1. From the test cohort, the responder
pool lane generated 34,026,026 reads (17,013,013 pairs)
while the non-responder pool lane generated 34,236,380
reads (17,118,190 pairs). Inspection of raw reads using
FASTQC analysis indicated some problems, in particular
overrepresentation of particular sequences. These were
discovered to correspond to the ends of amplicons, i.e.
primers and adjacent sequence.
Alignment
33,761,231 responder reads and 33,965,033 non-respon-
der reads aligned back to hg19 (99.2% for both pools), of
which 31,960,774 and 32,008,412 reads aligned back to
the target region, respectively. Of these, 31,082,806 and
31,143,590 reads had unique alignments to the target
region (Table S1 in Additional file 1).
The median coverage across the target region was
19,200 for responders (range 0-171,197) and 20,220 for
non-responders (0-177,376). 99.28% and 99.10% of tar-
geted bases had coverage ≥ 4 for R and NR, respectively.
Figure S1 in Additional file 2 shows the number of reads
uniquely mapped to each base of the target region. We see
spikes of very high coverage that correspond to amplicon
ends overrepresented in sequencing [22].
Coverage was found to be relatively low for one of the
two pools for two of the 23 amplicons. The responders
have very low coverage for the twentieth amplicon
(chr19:39,789,495 to 39,794,767) while the non-responders
have very low coverage for the first amplicon
(chr19:39,709,955 to 39,714,897) (Figures S1 in Additional
file 2 and Figure S2 in Additional file 3). Inspection of the
relevant PCR products showed only faint bands. Thus 2/
46 amplicon pools are likely to have suffered PCR failures
leading to low read counts that were very similar to back-
ground coverage or reads that aligned to the rest of the
genome that was not targeted via PCR. Fortunately, these
amplicons are not located close to IL28B.
Variant calling and association testing
CRISP detected 1221 SNVs and 118 indels (1339 var-
iants in total).
Validation with original GWAS SNP data and HapMap
data
CRISP called all 15 of the SNPs individually typed as
part of the GWAS as variants. The Spearman correla-
tion coefficients of MAF estimates between the pooled
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0.99 (R) and 0.95 (NR). Odds ratios were well correlated
(r =0 . 9 8 )w h i l ep - v a l u e sw e r ep o o r l yc o r r e l a t e d
(r = 0.35).
31 of the 35 HapMap SNPs in the target region were
called as variants; these had CEU MAFs of 0.013 or higher.
The four HapMap SNPs not called as variants had CEU
MAFs of 0.004, 0.005, 0.009 and 0.027. Spearman correla-
tion coefficients of CEU MAFs with MAFs estimated from
pooled MPS data were 0.84 (R) and 0.80 (NR).
Individual genotyping results
After taking into account obligate missingness, 86 sam-
ples with a genotyping rate below 89.47% were discarded,
leaving 819 samples. All 19 SNPs had genotyping rates
above 90%, with 17 SNPs having genotyping rates of 99%
or higher. SNP rs628973 was discarded due to a suspi-
cious distribution of genotypes (98.25% of genotypes het-
erozygous, Hardy-Weinberg test for combined sample
p = 9.78 × 10
-136). The other 18 SNPs had Hardy-Wein-
berg test p-values ranging from 3.09 × 10
-8 to 0.78,
minor allele frequencies ranging from 0.036 to 0.47, and
differential missingness p-values ranging from 0.095 to 1.
Hence, we performed association analyses using 819 sam-
ples with genotypes for up to 18 SNPs. A meta-analysis of
allelic test results found that 12 of these SNPs were
strongly (p < 0.001) associated with response (Table S2
in Additional file 1). Results under a genotypic genetic
model are presented in Table S3 in Additional file 1.
The four SNPs that best tagged the IL28B region haplo-
types were investigated further for their ability to predict
response to therapy. Response prediction was described in
terms of a recessive model, given that the response for
these SNPs was best described by a recessive model (Table
S3 in Additional file 1). The prediction of these four SNPs
in their recessive state was also investigated in conjunction
with their HLA-C allele, which has also been shown to be
important in predicting response to clear the Hepatitis C
virus (PLoS Medicine, accepted).
The association testing results using Fisher’se x a c tt e s t
b a s e do nt h eB W Aa l i g n m e n ta n dC R I S Pv a r i a n tc a l l s
from the MPS data with rescaled read counts show a
strong clustering of association signals around IL28B.B o t h
problem amplicons where PCR failures were suspected
were retained in the analysis. Figure 3 shows that both of
these regions produced spurious association signals with
amplicon 1 producing the most significant association sig-
nals overall.
The association testing of the nineteen SNPs chosen
for follow up individual genotyping in the independent
combined cohort validate the MPS association testing
results for the IL28B region, previous GWAS results and
other more recent re-sequencing results which are not
MPS derived, clearly implicating IL28B as the most
likely causal gene. SNPs rs4803221 and rs7248668 had
the highest association for a recessive model with an
OR = 4.74 and 4.85 respectively (Figure 4, Table S3 in
Additional file 1). Surrounding SNPs closest to this SNP
also show clear recessive effects. These results in combi-
nation are explained by the haplotype effect displayed in
Table 2.
Haplotypes and linkage disequilibrium
In our total cohort, six haplotypes were identified using
Haploview (Table 2 Figure 5a). Haplotype 2 had the
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Page 6 of 13Table 2 Table of haplotypes with odds ratios
NUMBER HAPLOTYPE HAPLOTYPE TAGGING SNP
A FREQUENCY (%) RESPONDERS (%) NON-RESPONDERS (%) P-VALUE OR
B (95% CI)
1 ATTGATCCTCTG rs8109886 43.2 48.4 39.6 4.00 × 10
-4 0.70 (0.57-0.85)
2 GCCAGCTGTAGA rs8099917/rs7248668 23.8 16.5 30.4 9.51 × 10
-11 2.20 (1.72-2.80)
3 GCTAGCTCCATG rs10853727 10.3 10.1 10.6 0.77 1.04 (0.75-1.43)
4 ATTGATCCTATG 9.8 12.3 7.8 2.40 × 10
-3 0.60 (0.43-0.83)
5 ATTAACTCTATG 1.9 2.2 1.7 0.47 0.79 (0.39-1.60)
6 GCCAGCTGTATG 1.4 1.1 1.6 0.39 1.49 (0.62-3.56)
The distribution of the six haplotypes in haplotype block 2 (Fig 4) bound by SNPs rs12980275 and rs7248668. The order is: rs12980275, rs12982533, rs8105790, rs688187, rs11881222, rs8103142, rs12979860,
rs48031221, rs10853727, rs8109886, rs8099917, rs7248668.
aSNP in the haplotype block 2 that tag the respective haplotypes.
bORs have been calculated as carriage of the haplotype vs non-carriage of the haplotype.
S
m
i
t
h
e
t
a
l
.
G
e
n
o
m
e
M
e
d
i
c
i
n
e
2
0
1
1
,
3
:
5
7
h
t
t
p
:
/
/
g
e
n
o
m
e
m
e
d
i
c
i
n
e
.
c
o
m
/
c
o
n
t
e
n
t
/
3
/
8
/
5
7
P
a
g
e
7
o
f
1
3(a) Location and D’ value for SNPs genotyped in this study
(b) Ethnic differences in linkage disequilibrium across the IL28B gene region 
Figure 5 IL28B Haplotype Blocks. (a) Location and D’ values for the SNPs genotyped in this study. Linkage disequilibrium blocks determined
from our cohort data using Haploview. HapMap SNPs genotyped in multiple populations shown in the header map in each case. (b) Ethnic
differences in linkage disequilibrium across the IL28B gene region. r
2 values are for the currently available SNPs genotyped in different ethnic
groups, with the designated SNPs compared to rs12980275.
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Page 8 of 13most significant association with failure to respond to
therapy. This was tagged by rs8099917 and rs7248668,
and largely by rs4803221. These are also the SNPs with
the highest odds ratios for homozygotes.
Predictive value for failure to respond
To evaluate the utility of the SNPs to predict treatment
failure we have compared the sensitivity, specificity, posi-
tive (for treatment failure, PPV) and negative predictive
values for the SNP minor allele homozygotes. The best
four are shown in Table 3. The PPV for treatment failure
is likely to be the most useful parameter clinically (see
discussion). The SNPs rs4803221 GG (PPV of 77.1, CI
62.7-88.0); rs7248668 AA (PPV 78.3, CI 63.6-89.1) both
perform better than the SNPs currently used in testing
rs8099917 GG (PPV 73.3, CI 58.1-85.4) and rs12979860
TT (PPV 68.3; CI 59.2-76.5) in this sample. However, the
confidence intervals indicate that they may perform bet-
ter, worse or equivalently at a population level.
We have recently identified that combination of carrier
status for the rs8099917 minor allele with HLA-C C2C2
homozygosity predicts treatment failure (PPV of 80.3) bet-
ter than either genotype alone (PLoS Medicine, accepted),
and more people have this genotype than are homozygous
for the minor alleles. Here all the haplotype 2 SNPs
(rs4803221 G, rs7248668 A, and rs8099917 G) perform
similarly (PPV 78.6, 79.7, 80.3), and better than
rs12979860 T (PPV 73.1) (Table S4 in Additional file 1).
The maximum proportion of the population identified as
having a non-responder genotype is by including those
with minor allele homozygosity (rs4803221 GG, PPV 77.1)
with those who are carriers of rs4803221 G and are HLA-
C C2 homozygotes (PPV 78.6). This is 7.7% of the respon-
der cohort, and 19.9% of the non-responders (Table S5 in
Additional file 1). Although SNP rs1297860 T homozygos-
ity plus T carriers with HLA-C C2 homozygosity predicts
a higher proportion of people who will fail to respond
(33.2% of non-responders), it mis-classifies more respon-
ders (17.1% responders).
In silico analysis of transcription factor binding sites and
methylation sites in the proximal promoter region
A CpG island encompassing SNPs rs12978960 and
rs4803221has been identified on the UCSC human gen-
ome draft by Miliak and Hillier (Figure 6),. The major
allele for each SNP comprises the C of a CpG dinucleo-
tide. Transcription factors that might differentiate between
the haplotypes were sought using the program Ali Baba
(Figure 6), which identifies transcription factor sites based
on core recognition motifs. Several were identified which
varied according to SNP present on the haplotype.
Discussion
After the discovery that rs8099917 and rs12978960 pre-
dicted PegIFN/R response in hepatitis C treatment, much
effort has gone into establishing which of these is more
likely to be causal, or to be the most useful in a diagnostic
test [23,24]. We identified eighteen SNPs in the putative
promoter region of IL28B using massively parallel sequen-
cing on pooled responders and non-responders, which
predicted response to PegIFN/R. These eighteen SNPs
collapse to six haplotypes that predict response according
to tagging by their minor alleles. The minor allele for
SNPs rs8099917, rs7248668, and rs4803221 were all found
on one haplotype, haplotype 2, which had the highest
OR (recessive model) for predicting treatment failure.
The minor allele of SNP rs4803221 is also found on
the rare haplotype 6. Minor alleles from SNPs rs12979860,
rs11881222, rs688187, rs12982533, rs35790907, rs1298
2533, rs12980275 were found on this haplotype and two
to three others (with MAF > 1%).
The LD block varies between ethnic groups. Japanese
and Chinese have fewer common haplotypes, with vir-
tually complete linkage between rs8099917, rs12978960,
and the 3’ end of the gene. In this population any of the
SNPs predict treatment failure with similar precision.
People of European descent, Hispanics and Indians have
more common haplotypes. In the former two we know
that haplotype 2 best predicts failure to respond, with
homozygotes for haplotype 2 best predicting treatment
failure. There is some recombination between the SNPs
tagging haplotype 2, and then the best two are rs7248668
(next to rs8099917) and rs4803221 (next to rs12979860,
also on the rare hapotype 6). The African population has
the shortest LD block, with a boundary between
rs12979860 and rs8099917, and previous work has shown
that the major effect of this African haplotype lies
between this point and the 3’ end of the gene (Ge et al,
2009). The causative SNPs or SNP, or other genetic var-
iant, is therefore most likely to be in this section of the
Table 3 Prediction of failure to clear of virus on therapy with PegIFN/R with homozygote non-responder SNPs (based
on 404 responders and 464 non responders of European origin)
Genotype Sensitivity (95% CI) Specificity (95% CI) Positive predictive value (95% CI) Negative predictive value (95% CI)
rs4803221 GG 8.4 (6.0-11.4) 97.0 (94.7-98.5) 77.1 (62.7-88.0) 47.1 (43.5-50.7)
rs7248668 AA 8.1 (5.7-11.0) 97.3 (95.1-98.7) 78.3 (63.6-89.1) 47.0 (43.4-50.5)
rs8099917 GG 7.4 (5.2-10.3) 96.8 94.5-98.3) 73.3 (58.1-85.4) 46.8 (43.2-50.4)
rs12979860 TT 18.9 (15.4-23.0) 89.5 (85.9-92.5) 68.3 (59.2-76.5) 48.0 (44.2-51.8)
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Page 9 of 13gene, which includes promoter variants, intronic, codon
changing, and 3’untranslated SNPs, any of which could
be, or could contribute with others, to the functional
effect of the haplotype. However, Ge et al identified an
effect of rs8099917 independent of this block in African
Americans, indicating multiple, variable, haplotype effects
on gene function.
The causative haplotype
Each of the haplotypes has putative immune transcrip-
tion factor sites distinguishi n gi tf r o mt h eo t h e r s .N o t a -
bly, the haplotype 2 SNP, rs4803221, is in the CpG
island, and removes a CpG site. The SNP rs12978960 is
the only other common SNP also in this region, and the
variant on haplotype 2 also removes a CpG site. There-
fore, two potential methylation sites are missing from
haplotype 2, and none or one methylation site from the
haplotypes corresponding to response. Methylated DNA
is resistant to unfolding and corresponds to reduced
expression. We hypothesise that increased methylation
leads to reduced expression of IL28B, and the interferon
sensitive genes (ISGs) upregulated by it, in the responder
haplotype; which is then responsive to interferon alpha
stimulation on therapy. Two studies have identified that
IL28B non-responders have high ISG expression in
infected hepatocytes, and that high ISG levels indepen-
dently predict poor response to therapy [25]. However
w e ,a n do t h e r s ,h a v ef o u n dt h at the non-responder hap-
lotype is associated with reduced expression in peripheral
blood of healthy controls [3,4]. Other authors have also
found no evidence for an effect of IL28B genotype on
ISG expression in uninfected hepatocytes [26]. This sug-
gests expression of IL28B and ISGs are context
dependent.
Haplotype 2 is clearly the major causative haplotype.
The causative SNP or SNPs will probably best be sought
Figure 6 Putative transcription factor and methylation sites on IL28B haplotypes. The 6 haplotypes identified using Haploview are shown.
SNPs changing CpG sites in the region identified as methylated by the Miklem and Hillier method (unpublished, UCSC Draft Human Genome)
are boxed in red. Predicted transcription factor binding sites different between haplotypes were identified using Ali Baba [29]. Note these
recognition site differences are from in silico analyses only, and serve as a proof of principle that the haplotype sequence differences are
sufficient to alter response to transcription factors.
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disequilibrium is lowest, allowing breaking up of the
large haplotype block and thus allowing inference of the
relative effects of each SNP. The task of demonstrating
the basis for causality, even of haplotypes, is not trivial,
and thus far has not been achieved for most of the
genetic associations currently identified by GWAS. In
the short term, diagnostic tests are likely to be depen-
dent on haplotype tagging SNPs, in combination with
other parameters such as IP10, 25 hydroxy vitamin D3,
and HLA-C genotype. From genotyping, SNP rs4803221
and HLA-C C2C2 provides the best predictive value.
Clinical utility
Therapy for HCV infection is currently undergoing a
radical transformation with the advent of Direct Acting
Antivirals (DAAs) such as boceprivir and telaprivir to the
PegIFN/R backbone [27]. Cure rates are substantially
higher (20-30%), and these drugs have the potential to
reduce treatment duration. However, enthusiasm for
these regimens is tempered by the substantially lower
cure rates (~30%) in previous PegIFN/R null responders.
In all those failing single DAA-based therapy, future
treatment with multiple DAA-based combinations with
or without PegIFN/R may be compromised by the devel-
opment of drug resistance. Further, HCV eradication
using single DAA-based strategies, particularly in pre-
v i o u st r e a t m e n tf a i l u r e sa p p e a r st ob eIL28B genotype
dependent. In this context, predicting non-response
rather than success is paramount since the former should
perhaps have therapy deferred until multiple DAA-based
combinations become available. The present results
t h e r e f o r ep r o v i d eas t r o n gr a t i o n a l ef o rt h eu s eo f
rs4803221 in combination with the HLA-C genotype,
such that those with non-response genotypes be consid-
ered for future regimens rather than single DAA-based
therapy, signalling the emergence of truly personalized
treatment for HCV infection.
Resequencing for GWAS with MPS
Due to cost constraints the current approaches for GWAS
re-sequencing usually employ pooling strategies. Large
pool sizes make it difficult to differentiate between rare
variants and sequence errors, while the variable represen-
tation of each haplotype among those sequenced makes
MAF estimates more variable and complicates association
testing. However, if analysis is performed carefully it is
possible to not just identify variants but to also meaning-
fully assess the association signals. This is the first time
that this region has been re-sequenced with MPS to dis-
cover novel variants that could determine the response to
hepatitis C treatment. No rare variants tagging haplotype
2 were identified, but this does not exclude the existence
of a synthetic association via multiple rare variants. Such
rare variants would have to be predominantly on haplo-
type 2.
MPS resequencing in GWAS is not without problems.
Targeting of the region is required, usually with PCR, for
smaller association signals. PCR can lead to amplification
artefacts that can be alleviated, at least in part, with
advanced lab protocols [22] which would result in more
uniform coverage than what was achieved in this study.
Failure to assess amplicon pool performance can clearly
lead to false positive association signals in MPS resequen-
cing studies. Genomic regions with high homology, such
as the one that IL28B is located in, have low mapability,
resulting in reduced ability to detect new variants. Another
problem is that short reads can misalign to a different ver-
sion of the homologous sequence than the one they were
derived from, resulting in alignments with mismatches
that are incorrectly identified as putative variants. Using
an alignment program such as BWA, which allows for
gapped alignment around indels, is crucial. Thus this
study has provided important insights for future resequen-
cing studies following up GWAS hits.
Although we found no evidence for SNPs with even big-
ger odds ratios than the haplotype taggers, rare variants
(< 5%) would not have been detected in this study, since
with the large pool sizes used the lowest theoretical MAF
would be similar in magnitude to the frequency of sequen-
cing errors. To improve sensitivity for such detection,
smaller pool sizes could be used or samples sequenced
individually (e.g. using barcoding); these options become
increasingly feasible as the cost of MPS decreases. Newer
sequencing technologies generate longer reads, which will
allow more read pairs to be aligned uniquely to this highly
repetitive region, resulting in higher coverage and more
power to detect variants. Protocols to reduce PCR amplifi-
cation artefacts will also be refined so that MPS of PCR
products can be more effectively performed, resulting in
more even coverage and thus better ability to detect
variants.
Conclusions
Pooled massive parallel sequencing followed by indivi-
dual genotyping in a large cross sectional cohort has
allowed identification of the common SNPs around the
IL28B gene which best predicted response to PegIFN/R
for the treatment of hepatitis C. We argue that prediction
of failure to respond to therapy is the most useful para-
meter for clinical management. SNPs tagging haplotype 2
provide the best positive predictive value of treatment
failure. This haplotype was conserved from the 3’ end of
t h eg e n et o8 k bu p s t r e a mo ft h e5 ’ end of the gene in
people of European descent. This causal haplotype con-
tains different putative transcription factor binding sites
and two SNPs predicted to abolish the methylation
potential of CpG sites located within a CpG island. These
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Page 11 of 13data are consistent with the haplotypes altering drug
response through regulation of expression of IL28B.
Additional material
Additional file 1: Tables S1 to S5. Table S1: number of reads aligned
for each comparison. Table S2: results of the allelic test for 18 individually
genotyped SNPs. Table S3: results of the genotypic test for 18
individually genotyped SNPs. Table S4: prediction of failure to clear virus
on therapy with PegIFN/R with HLA-C/IL28B SNP combination. Table S5:
HLA-C combination with IL28B SNPs.
Additional file 2: Figure S1. Coverage of the target region for
responder and non-responder pools. Coverage spikes around the
locations of primers (indicated by green dotted lines).
Additional file 3: Figure S2. Coverage of amplicons 1 and 20 for
responders (black) and non-responders (red).
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